| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Mupadolimab manufacturers
- Mupadolimab
-
- $133.00
-
2026-08-08
- CAS:2451856-97-4
- Purity: > 95%
- Supply Ability: 10g
|
| | Mupadolimab Basic information |
| Product Name: | Mupadolimab | | Synonyms: | Mupadolimab;Research Grade Mupadolimab(DHD46604);Mupadolimab (anti-CD73);CPI-006;Research Grade Mupadolimab | | CAS: | 2451856-97-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Mupadolimab Structure]() |
| | Mupadolimab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | Mupadolimab Usage And Synthesis |
| Uses | Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells[1]. | | in vivo | Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice[1]. | Animal Model: | NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection, daily for 15 days | | Result: | Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein. |
| | References | [1] Miller R A, et al. Clinical results with a B cell activating anti-CD73 antibody for the immunotherapy of Covid-19. medRxiv, 2021. |
| | Mupadolimab Preparation Products And Raw materials |
|